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Aim: This study analysed the effect of selective ß1-blockade on 
neuromuscular recruitment characteristics during progressive endurance 
exercise. Methods: Ten healthy subjects ingested a selective ß1-blocker, 
acebutolol (200mg b.d.), for 7 days (for one of two cycling trials), with a 10-
day wash out period between trials. On the last day of acebutolol ingestion 
subjects performed three successive 15 min rides at 30%, 50% and 70% of 
their peak power output and then cycled at increasing (15 W.min-1) work rates 
to exhaustion. Force output, heart rate, submaximal VO2, rate of perceived 
exertion (RPE), electromyographic (EMG) data and blood lactate was 
captured during the cycling activity. 
Results: Peak work rate (270 + 111 W vs 197 + 75 W, CON vs BETA, P < 
0.01), time to exhaustion (49.7 + 23.2 min vs 40.3 + 23.7 min, CON vs BETA, 
P < 0.05) and heart rate (mean, for the full ride 135.5 + 38.3 b.min-1 vs 111.5 
+ 30.0 b.min-1  CON vs BETA, P < 0.05) were significantly lower for the group 
who ingested ß1-blockade (BETA) compared to the control group (CON). 
Although not significant, submaximal VO2 was reduced in BETA during the 
ride, while RPE was significantly higher during the ride for BETA (P < 0.01). 
Mean integrated electromyography (IEMG) was higher in the BETA group 
although these differences were not significant. Mean power frequency values 
(MPFS) of the BETA group showed a significant (P < 0.05) shift to the upper 
end of the spectrum in comparison to the control group. Lactate values (11.7 
+ 3.5 mmol.l-1 vs 7.1 + 4.1 mmol.l-1 CON vs BETA) were significantly lower (P 
< 0.05) at exhaustion in BETA. 
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Conclusions: Significant reductions in cycling performance were found when 
subjects ingested ß1-blockers. This study has shown significant shifts to the 
upper end of the EMG frequency spectrum after ß1-blocker ingestion, which 
could be caused by a change in neuromuscular recruitment strategy to 
compensate for the impaired maximal exercise capacity.  
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Individuals receiving β-adrenergic receptor blocking drugs often complain of 
muscle fatigue. Both non-selective β1- + β2-blockers and selective β1-blockers 
reduce most individuals’ capacity to exercise {769}{770}{771}. Even when β-
blockers possess intrinsic sympathomimetic (β1-agonist) activity (ISA), to limit 
the reduction in cardiac output, there is no improvement in exercise tolerance 
{40}{772}. A failure of β-blockers with ISA to improve sub-maximal exercise 
tolerance {77}{50}{773}{777} suggests that β-blockade does not accelerate 
fatigue simply by reducing the supply of O2 to the active muscles. Beta-
blockade either increases {774}{775} or has no effect on plasma lactate 
accumulation during exercise {769}{50}{770}. Beta-blockade also does not 
increase muscle glycogenolysis {779}{77} Plasma [glucose] during exercise is 
either decreased {50}{775}{776}{771} or unaffected by β-blockade {234}{777}. 
Only the mobilisation of non-esterified fatty acids (NEFA) is consistently 
decreased by β-blockade {777}{50}{780}{781}. However, whether lower 
plasma [glucose] or [NEFA] is involved in the reduced exercise endurance 
capacity during β-blockade is open to question. Intravenous infusion studies 
have shown that reversal of the decreases in circulating [glucose] and [NEFA] 
with β-blockade do not improve exercise capacity {781}{776}.  
 
Since changes in metabolism do not readily explain the impaired sub- 
maximal exercise capacity during β-blockade, other potential causes of early 
fatigue have to be considered. One possibility is that β-blockade may affect 
muscle recruitment activity from the central pathways of control. In cycle 
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exercise the integrated electromyographic (IEMG) activity is known to 
increase with increased exercise intensity {185}. During continual heavy work 
at a constant load, an increase in IEMG is observed and is interpreted as a 
sign of muscle contraction failure {46}. More information detailing the motor 
unit action potentials can be gained by studying the mean power frequency 
spectrum (MPFS).  
 
The only experiments to the author’s knowledge that has been conducted to 
study the influence of ß-blockers on the EMG pattern under exercise 
conditions was Tesch et al. {737} who discovered no differences in IEMG or 
MPFS during cycling, but did find a decrease in MPFS during ß-Blockade in 
comparison to the control group. This could be indicative of muscle fatigue or 
decreased conduction velocity of the nerve fibers {36}{39}. MPFS was 
calculated by describing data captured at 90 W initial work rate, and all 
subsequent data was normalised against it. However, this normalisation 
technique can be questioned as Ebenbichler et al. {220} concluded that MVC 
is the most reliable form of reference when conducting MPFS analyses. This 
has to be considered throughout investigation of biological signals in which 
the electrical and mechanical activities of the recruited motor units are 
summated {194}. Second, Derman {191} examined IEMG patterns of 
exercising subjects ingesting ß-blockade and found no difference in MVC but 
significantly higher IEMG activity in the subjects who ingested ß-blockade. 
Derman {191} concluded that the higher IEMG was due to additional 
recruitment of non-fatigued skeletal muscle fibers to maintain the same work 
rate. However in this study MPFS was not determined. Therefore, the 
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hypothesis for this study is that during submaximal exercise to exhaustion, 
ß1-blocker ingestion will result in an altered neuromuscular recruitment 
pattern, which will be shown by a changed IEMG and MPFS signal. 
Accordingly, we examined the effects of acebutolol, a selective ß1-blocker 
with intrinsic sympathetic activity on IEMG and MPFS during successive cycle 





Ten healthy males volunteered for the study, who were physically active on a 
regular basis. Three subjects were unable to complete due to adverse effects 
such as headaches, dizziness and nausea whilst ingesting beta blockade. 
The mean age of the remaining subjects was 26.1 + 2.1 years (range 23 – 30 
years), height 181 + 9 cm (range 169 – 194 cm), weight 78.6 + 9.7 kg (range 
62 – 94 kg) and percent body fat 14.8 + 2.7% (range10.6 - 17.7%). The mean 
lean thigh volume (LTV) was 6492 + 928cc (range 4629 – 7381cc). All 
subjects were well informed about possible risks associated with the 
experiment and gave their informed consent before participation. 
 
Preliminary testing 
To determine peak power output (PPO), a modified protocol as described by 
Hawley and Noakes {146} was used. Subjects performed a 10-minute warm 
up on an electrically braked cycle ergometer (Lode, Groningen, Netherlands). 
The starting power output was determined by multiplying the subject’s body 
weight by 2.5 W. The load was subsequently increased every 150s by first 50 
W and then 25 W until the subjects were unable to maintain force output or 
pedalling frequency dropped from 90 to < 50 revolutions. min.-1. PPO was 
defined as the last completed work rate in watts plus the fraction of time spent 




Following the progressive exercise tests, the subjects ingested acebutolol for 
one of the two phases of the trial in a random order. The trials took place over 
one week periods with a 10 day wash out in between trials. Subjects were 
instructed to consume two 200 mg capsules between 0700 and 0900 h before 
breakfast for a period of seven days.  
 
Blood sampling 
On the last day of each phase the subjects were instructed to report the 
laboratory. An 18-guage Teflon cannula (Jelco, Johnson and Johnson, 
Halfway house, South Africa) was positioned in an antecubital vein and 
connected to a three way stop cock (Uniflex, Mallinckrodt, Hennef-Seig, 
Germany). This cannula was flushed periodically with 2-3 ml of sterile saline 
containing heparin (5 IU ml-1) and was used for the collection of venous blood 
samples (10 ml) at rest and during exercise. Venous blood samples (10ml) 
were drawn at rest, at the end of each 15 min work rate and at exhaustion. 
The samples were then divided into aliquots, which were put into an ice-cold 
tube containing potassium oxalate and sodium fluoride for later 
determinations of lactate concentrations. The tubes were centrifuged at 3000-
x g for 10 minutes at 4ºC immediately after the completion of the trial and the 
supernatants were stored at -20ºC for later analyses of plasma lactate. 
Plasma lactate concentrations were measured with spectrophotomeric 
(Beckman Model 35, Beckman Instruments Inc., Fullerton, Ca, USA) 
enzymatic assays (Lactate PAP, BioM (rieux, Lyon, France; NEFA half-micro 
test; Boehringer Manheim, Germany). 
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Maximal isometric voluntary contraction (MVC) 
To normalise EMG recordings during cycling it was first necessary to perform 
maximal isometric force output testing, which is not affected by ß-blocker 
ingestion {759}. The strength of the subjects’ right knee extensors were 
measured on an isokinetic dynamometer (Kin-Com Chattanooga Group Inc., 
USA). Subjects sat on the dynamometer and their hips, thighs and upper 
bodies were firmly strapped to the seat. In this position their hip angle was at 
100° angle of flexion. The right lower leg was then attached to the arm of the 
dynamometer at a level slightly above the lateral malleolus of the ankle joint 
and the axis of rotation of the dynamometer arm was aligned with the lateral 
femoral condyle. The dynamometer arm was then set so that the knee was at 
a 60° angle from full leg extension. Each subject performed four sub-maximal 
familiarisation contractions prior to performing two maximal MVC’s; the latter 
of which was used for subsequent analyses. All subjects were encouraged 
verbally to exert maximal effort during both MVC’s. 
 
Progressive submaximal exercise 
As with the preliminary PPO testing, Lode cycle ergometers were used. After 
taking a venous blood sample and measures of heart rate at rest, the subjects 
performed three successive 15 min rides at 30, 50 and 70% of their PPO and 
subsequently cycled at increasing 15 W.min-1 until they could not maintain 
force (Figure 1). The same ride was performed for both the controls (CON) 




Recordings of heart rate and perceived exertion  
Heart rate was recorded at rest and then recorded along with rate of 
perceived exertion (RPE) {782} at 10, 25, 40 minutes and at exhaustion 
(Figure1).  
 
Submaximal VO2 testing  
During the final 5 minutes of each 15 min work rate and at exhaustion, 
subjects wore and breathed through a mask connected to an Oxycon Alpha 
automated gas analyser (Mijnhardt, Netherlands). Before each test, the 
analyser was calibrated with a Hans Rudolph 5530, 3L syringe (Vacuumed, 
Ventra, USA) room air and a 5% CO2: 95% N2 gas mixture. Analyser outputs 
were processed by a computer, which calculated one minute ventilation, 
oxygen consumption and carbon dioxide production values for each breath. 
Oxygen consumption values were the average of the highest values 
measured over 60s in the final work rate. VO2 was then determined by 
dividing the oxygen consumption value by the body weight of the subject 
(ml.kg‾¹.min‾¹). 
 
Electromyographic (EMG) testing 
Prior to maximal isometric strength testing on the Kin-Com isokinetic 
dynamometer, EMG electrodes were attached to the subject’s lower limb 
midway between the superior surface of the patella and the anterior superior 
iliac crest of the “belly” of the rectus femoris. The overlying skin on the 
muscles was carefully prepared. Hair was shaved off, the outer layer of 
epidermal cells abraded, and oil and dirt were removed from the skin with an 
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alcohol pad. Triode electrodes (Thought Technology USA) were placed on the 
muscle sites as described above, and linked via a fibre-optic cable to the 
Flexcomp/DSP EMG apparatus (Thought Technology USA) and host 
computer. The electrodes were heavily taped down with cotton swabs to 
minimise sweat-induced interference. The EMG data was filtered with a 50Hz 
line filter to prevent electrical interference from electrical sources and was 
automatically anti-aliased by the hardware (Thought Technology USA). Each 
activity was sampled at a 1984 Hz capture rate for 5-second bouts. 
Recordings were taken on the second maximal isometric trial and during the 
cycling trial at 10, 25, 40 minutes and at exhaustion thus yielding a raw signal. 
MVC EMG data was recorded before both cycle rides to ensure similar 
normalisation of EMG in both trials. The raw data were divided into 5 x five 
second epochs. The first epoch included all data collected during the second 
MVC trial, and the remaining four epochs included data collected on the ride 
at 10, 25, 40 minutes and at exhaustion.  
 
The EMG signals were full wave rectified, movement artifact removed using a 
high-pass second order Butterworth filter with a cut off frequency of 15 Hz, 
then smoothed with a low-pass second order filter with a cut off frequency of 5 
Hz. This was performed using MATLABTM gait analyses software. This 
integrated data (IEMG) was used for subsequent analyses. 
 
The spectrum of the frequency for each epoch of data collected during the 
cycle ride was assessed using the raw EMG data by using a fast Fourier 
transformation algorithm. The analyses for frequency spectrum were 
 12 
restricted to frequencies of the 5-500 Hz range, due to the EMG signal 
content consisting mostly of noise when it is outside of this bandwidth. The 
frequency spectrum from each epoch of data was compared with that derived 
from the MVC, and the amount of spectral compression was estimated. This 
technique was performed as described by Lowery et al. {48}, which is a 
modification of the work of Lo Conte and Merletti {47} and Merletti and Lo 
Conte {729}. The spectrum of the raw signal of each epoch was obtained and 
the normalised cumulative power at each frequency was calculated for each 
epoch. The shift in percentile frequency was then examined (i.e. at 
0%...50%...100% of the total cumulative). The percentile shift was then 
estimated by calculating the mean shift in all percentile frequencies 
throughout the mid-frequency range (ie. 5-500 Hz). This method has been 
suggested as a more accurate estimate of spectral compression than median 
frequency analyses, which uses single value of (50th) percentile frequency 




A two-way ANOVA for repeated measures was used to evaluate statistical 
significance of all the variables measured. A Scheffe’s post hoc test was used 
to detect differences over time and between groups. Single comparisons 
between treatments were analysed with a paired Students t-test using two-
tailed values of P. Significance was accepted at P < 0.05. All data are 





Significantly lower values (P < 0.05) during the cycle ride were found in BETA 
compared to CON for maximum power output (PWATT) (P < 0.01) and time to 
exhaustion (TIME) in BETA (Table 1). 
 
Heart rate increased significantly less (P < 0.05) (Figure 2) for BETA in 
comparison to CON and both groups responded similarly over time. Mean 
heart rate for the total ride was 111.5 + 30.0 b.min-1 for BETA and 135.5 + 
38.3 b.min-1 for CON. In BETA the reduced heart rate was accompanied by a 
trend for lower submaximal VO2 values with both groups increasing 
significantly over time (P < 0.05) (Figure 3). Mean submaximal VO2 values for 
the duration for the ride were 32.0 + 8.3 ml.kg‾¹.min‾¹ for BETA and 38.1 + 9.6 
ml.kg‾¹.min‾¹ for CON. 
 
RPE was significantly greater for BETA than CON (P < 0.01) (Figure 4) and 
mean RPE values for the total ride were 6.1 + 3.6 for BETA and 4.7 + 3.6 
CON.  
 
IEMG values showed a trend to increase by 34.7, 30.2, 44.1 and 64.4% at 10, 
25, 40 min and exhaustion respectively for BETA in comparison to CON. The 
BETA group also showed a large standard deviation for IEMG data at 
exhaustion (Figure 5). The mean IEMG for the total ride was 56.9 + 25.4 % for 
BETA and 29.4 + 4.0 % for CON. There was a significant (P < 0.05) shift to 
the upper portion of MPFS in BETA with a mean of 1.15 + 0.03 in comparison 
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to a shift to the lower portion of MPFS in CON, which showed an average of 
0.78 + 0.07 for the total ride (Figure 6).  
 
Lactate concentrations were significantly less for BETA in comparison to CON 
(7.1 + 4.1 mmol.l-1 BETA; 11.7 + 3.5 mmol.l-1  CON) at exhaustion (Figure 7) 




The results of this study indicate that ß-blockade significantly effects 
neuromuscular recruitment activity during submaximal exercise. Maximal 
exercise capacity was reduced by ingestion of selective ß-1 blockade, as 
reported by most investigators {40}{27}. The impaired maximal exercise 
capacity may reduce heart rate and VO2 as is shown in this study. It is also 
well documented that an increased perception of effort will reduce exercise 
performance in healthy individuals who have ingested ß-blocker {35}{760}, 
which is shown in this study by an increase in RPE for BETA. It is has been 
proposed that this increase in perception of effort results from an inability of 
healthy individuals to compensate for the decrease in heart rate by increasing 
stroke volume as it is has been maximised as an adaptation effect of exercise 
training {32}. These changes in RPE may also be related to neuromuscular 
recruitment differences as shown in this study. 
 
IEMG data firstly showed similar results to Derman et al. {191}, where IEMG 
tended to increase in subjects who ingested ß-blockade. This could be due to 
a central mechanism projecting increased neural output due to the reduced 
maximal exercise capacity. Moritani and Yoshitake {59} showed a linear 
increase for IEMG/VO2 in normal subjects. However the BETA group had a 
significantly lower VO2, yet IEMG was higher. This would indicate that there is 
a higher neural input to compensate for the reduced VO2. Another possibility 
is that there was a higher recruitment of non-fatigued muscle fibres {191}, 
when subjects were on ß-blocker.  
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The large standard deviations for final force output and IEMG activity in the 
BETA group show that certain subjects are more vulnerable to reduced 
exercise tolerance when ingesting ß-blockade. This finding is supported by 
Derman {191} who showed that not all the subjects’ performance capacities 
were equally affected following the ingestion of ß-blockade. 
 
There was a significant shift to the upper portion of MPFS in BETA, which 
indicates an increase in firing rate to recruit more motor units {763} in 
response to the reduced exercise capacity. {484}{485}{63}{480}. This shift 
towards the upper portion of MPFS could have been caused by an increase in 
muscle fiber conduction velocity (MFCV) {186} from an up regulation in central 
command {697}{313}. This change in central command may be an attempt to 
recruit more type II muscle fibers as ß-blockade will cause the impairment of 
type I fibers during cycling {37}, resulting in a greater use of type II fibers 
which have a lower fatigue threshold. Furthermore, this finding is supported 
by Kupa et al {165}, who showed that the greater proportion of type II muscle 
fibers would result in a shift to the upper end of the spectrum. This is due to 
type II fibers having a greater maximum rate of repolarization and 
depolarisation compared to type I fibers and indeed produce an action 
potential that has a lesser duration {166}. Action potentials that have a shorter 
duration, contribute high frequency components to the EMG spectrum that 
produce a greater value of MPFS {165}. This increased use of type II fibers, 
which have a lower fatigue threshold may have also been a factor in the early 
termination of exercise in BETA. 
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However, it is also possible that the difference in MPFS could be from muscle 
changes. First, it has been suggested that the decline in MPFS is as a result 
of increased lactate concentrations causing a lowering of pH {104} and a 
consequent reduction in MFCV {105}{63}{106}{107}. In this study, lactate 
concentrations were significantly less for BETA, which does suggest a 
possible cause for the difference in MPFS. Conversely, it has also been 
shown in McArdle’s disease patients that MPFS declined during MVC, in the 
absence of any lactate and MFCV changes, therefore suggesting that factors 
other than increasing lactate would influence MFCV {111}. The change in 
MPFS could also be from an increase in muscle temperature in BETA, as the 
reduced cardiovascular capacity will be requiring a higher amount of effort to 
sustain the same given workload as CON. Bigland-Ritchie {186} showed that 
by heating a muscle it would increase conduction velocity and therefore 
produce a shift to the upper portion of MPFS. 
 
Blood lactate concentrations were lower in the BETA group at fatigue, which 
is supported by some investigators {183}{34}. However, other studies show 
conflicting results {32}. In our study, BETA subjects fatigued at lower power 
outputs, which will inevitably cause a decrease in absolute lactate values. 
Therefore, reduced lactate may be caused simply by reduced cycling intensity 
at fatigue. 
 
In conclusion this study supports earlier studies that selective ß1-blockade will 
limit prolonged exercise endurance. Furthermore, this study has shown that 
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subjects who have ingested ß-blockers have altered EMG frequency 
spectrum, which could result from a change in the neuromuscular recruitment 
strategy in an attempt to generate more power to compensate for the 
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Table 1. Peak watts (PWATT) reached at the point of cycling exhaustion and 
time taken to reach exhaustion (TIME) for both control (CON) and subjects 
who have ingested ß-blocker (BETA). 
 
 CON BETA 
PWATT 270.8 + 111.6 ** 197.45 + 75.7 
TIME 49.7 + 23.2 * 40.33 + 23.7 
 
All values are mean + SD 
**-P < 0.01 PWATT CON vs BETA 




Figure 1. Progressive cycle exercise test protocol. Rate of perceived exertion 
(RPE), electromyography (EMG), heart rate (HR) and VO2 were all recorded 
at 10, 25, 40 minutes and at exhaustion during the ride. 
 
Figure 2. Heart rate values captured at rest, 10, 25, 40 mins and exhaustion 
during the cycle ride for the ß-blocker group (BETA) and the control group 
(CON) (*P < 0.05 group effect). 
 
Figure 3. VO2 values captured at 10, 25, 40 mins and exhaustion ride for the 
ß-blocker group (BETA) and the control group (CON) during the cycle ride (*P 
< 0.05 increase for both groups over time). 
 
Figure 4. Rate of perceived exertion values captured at 10, 25, 40 mins and 
exhaustion ride for the ß-blocker group (BETA) and the control group (CON) 
during the cycle ride (*P < 0.01 main effect). 
 
Figure 5. Mean IEMG values a normalised as a % of MVC for both BETA and 
CONTROL, taken at 10, 25, 40 min and exhaustion. 
 
Figure 6. MPFS values normalised against MVC for both BETA and CON, 
taken at 10, 25, 40 mins and exhaustion. (*-P < 0.05 group effect). 
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Figure 7. Lactate samples taken at rest, at 15 minutes during the ride and at 
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Figure 1. Progressive cycle exercise test protocol. Rate of perceived exertion 
(RPE), electromyography (EMG), heart rate (HR) and VO2 were all recorded 
at 10, 25, 40 minutes and at exhaustion during the ride. 
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Figure 2. Heart rate values captured at rest, 10, 25, 40 mins and exhaustion 
during the cycle ride for the ß-blocker group (BETA) and the control group 
(CON) (*P < 0.05 group effect). 
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Figure 3. VO2 values captured at 10, 25, 40 mins and exhaustion ride for the 
ß-blocker group (BETA) and the control group (CON) during the cycle ride (*P 
< 0.05 increase for both groups over time). 
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Figure 4. Rate of perceived exertion values captured at 10, 25, 40 mins and 
exhaustion ride for the ß-blocker group (BETA) and the control group (CON) 
during the cycle ride (*P < 0.01 main effect). 
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Figure 5. Mean IEMG values a normalised as a % of MVC for both BETA and 
CONTROL, taken at 10, 25, 40 min and exhaustion.  
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Figure 6. MPFS values normalised against MVC for both BETA and CON, 
















Figure 7. Lactate samples taken at rest, at 15 minutes during the ride and at 
exhaustion in both CON and BETA groups. (**P < 0.01 CON vs BETA main 
effect) 
 
 
 
 
 
 
